logo

SITAGLIPTIN HCL

SITAGLIPTIN HCL

862156-92-1

SITAGLIPTIN HCL

862156-92-1

Therapeutic category

Antidiabetic

Standard package

Fiber drum, 50 Kg

Regulatory data

EDMF

Pharma-copoeias

in house

Production site

BENECHIM

< Back

SITAGLIPTIN HCL

Therapeutic category: Antidiabetic

Reference: 862156-92-1

Standard package​: Fiber drum, 50 Kg

Regulatory data​: EDMF

Pharma-copoeias​: in house

Production site​: BENECHIM

IUPAC name​​: 7-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]-5,6,7,8-tetrahydro-3-(trifluoromethyl)--[1,2,4]triazolo[4,3,-a]pyrazine hydrochloride (1:1) monohydrate.

Pharmaceutical Dose Forms:

oral tablet

Material Safety Data Sheet (MSDS): Download PDF

SITAGLIPTIN HCL

862156-92-1

Additional information

IUPAC name

7-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]-5,6,7,8-tetrahydro-3-(trifluoromethyl)–[1,2,4]triazolo[4,3,-a]pyrazine hydrochloride (1:1) monohydrate.

Pharmaceutical Dose Forms

oral tablet

Material Safety Data Sheet (MSDS)

Download PDF

https://moehs.com/wp-content/uploads/2022/11/EN__SITAGLIPTIN-HYDROCHLORIDE-MONOHYDRATE862156-92-1_07072023-2.pdf

< Previous | Next >

logo
Twitter Linkedin-in
  • Headquarters:
  • Pol. Ind. Cova Solera
  • c/Roma, 8-12 08191 Rubí.
  • Barcelona (Spain)
  • T +34 93 586 05 20
  • Fax +34 93 588 85 13
  • info@moehs.es

Partnering companies

The Board of Directors of the Center for Technological Development and Innovation, E.P.E (CDTI), in its meeting held on 02/23/2023, approved the participation of this center in the research and development project called SYNTHESIS OF A STIMULATOR ACTIVE PRINCIPLE OF SOLUBLE CYCLASE GUANYLATE by granting partially reimbursable aid.

The objective is focused on the development of a new method of chemical synthesis of an active ingredient that stimulates soluble guanylate cyclase.

The project will be carried out at the Rubí facilities. The project execution period is from 2022 to 2024 and they have a financeable budget of €1,862,213.00.
This project is co-financed by the European Union and CDTI.

The Board of Directors of the Center for Technological Development and Innovation, E.P.E (CDTI), in its meeting held on 02/23/2023, approved the participation of this center in the research and development project called SYNTHESIS OF AN ACTIVE INHIBITOR PRINCIPLE OF JANUS KINASE FOR THE TREATMENT OF ATOPIC DERMATITIS.”, by granting partially reimbursable aid.

The objective is focused on the development of a new method of chemical synthesis of a janus kinase inhibitor active ingredient for the treatment of atopic dermatitis.

The project will be carried out at the Rubí facilities. The project execution period is from 2022 to 2025 and they have a financeable budget of €1,940,409.
This project is co-financed by the European Union and CDTI.